A 52-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough
NCT ID: NCT05599191
Last Updated: 2025-06-10
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
PHASE3
825 participants
INTERVENTIONAL
2022-10-25
2026-05-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A 24-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough
NCT05600777
A Dose Escalation Study of BLU-5937 in Unexplained or Refractory Chronic Cough
NCT03979638
Assessment of the Pharmacokinetics of BLU-5937 Extended Release Prototypes and a BLU-5937 Immediate Release Reference Formulation
NCT05570539
Evaluation of S-600918 in Adults With Refractory Chronic Cough
NCT04110054
Clinical Study to Evaluate the Efficacy and Safety of Three Different Doses of BAY1817080 Compared to Placebo in Patients With Chronic Cough
NCT04562155
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
BLU-5937 25 mg
BLU-5937 oral dose 25 mg twice a day.
BLU-5937
Oral administration of BLU-5937 Tablets
BLU-5937 50 mg
BLU-5937 oral dose 50 mg twice a day.
BLU-5937
Oral administration of BLU-5937 Tablets
Placebo
Matching Placebo for BLU-5937 oral dose twice a day.
Placebo
Oral administration of matching placebo for BLU-5937 Tablets
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
BLU-5937
Oral administration of BLU-5937 Tablets
Placebo
Oral administration of matching placebo for BLU-5937 Tablets
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Refractory chronic cough (including unexplained chronic cough) for at least one year
* Women of child-bearing potential must use a highly effective contraception method during the study and for at least 14 days after the last dose
Exclusion Criteria
* Diagnosis of chronic obstructive pulmonary disease, bronchiectasis, chronic bronchitis, cystic fibrosis, pulmonary sarcoidosis, idiopathic pulmonary fibrosis, uncontrolled asthma, or other significant or progressive airway/respiratory disorder that might affect cough based on clinician assessment
* Respiratory tract infection within 4 weeks before screening
* Laboratory confirmed Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection at screening
* History of malignancy in the last 5 years
* History of alcohol or drug abuse within the last 3 years
* Has a positive serologic test for human immunodeficiency virus (HIV), hepatitis B virus surface antigen, or hepatitis C virus.
* Previous participation in a BLU-5937 trial
18 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Bellus Health Inc. - a GSK company
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
GSK Clinical Trials
Role: STUDY_DIRECTOR
GlaxoSmithKline
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
GSK Investigational Site
Litchfield Park, Arizona, United States
GSK Investigational Site
Scottsdale, Arizona, United States
GSK Investigational Site
Encinitas, California, United States
GSK Investigational Site
Mission Viejo, California, United States
GSK Investigational Site
Paramount, California, United States
GSK Investigational Site
Roseville, California, United States
GSK Investigational Site
Aurora, Colorado, United States
GSK Investigational Site
Colorado Springs, Colorado, United States
GSK Investigational Site
Clearwater, Florida, United States
GSK Investigational Site
Gainesville, Florida, United States
GSK Investigational Site
Miami, Florida, United States
GSK Investigational Site
Miami, Florida, United States
GSK Investigational Site
Miami, Florida, United States
GSK Investigational Site
Miami, Florida, United States
GSK Investigational Site
Orlando, Florida, United States
GSK Investigational Site
Lawrenceville, Georgia, United States
GSK Investigational Site
Normal, Illinois, United States
GSK Investigational Site
Oak Lawn, Illinois, United States
GSK Investigational Site
Ames, Iowa, United States
GSK Investigational Site
Iowa City, Iowa, United States
GSK Investigational Site
Kansas City, Kansas, United States
GSK Investigational Site
Topeka, Kansas, United States
GSK Investigational Site
Wichita, Kansas, United States
GSK Investigational Site
Crowley, Louisiana, United States
GSK Investigational Site
Shreveport, Louisiana, United States
GSK Investigational Site
Annapolis, Maryland, United States
GSK Investigational Site
North Dartmouth, Massachusetts, United States
GSK Investigational Site
Ann Arbor, Michigan, United States
GSK Investigational Site
Ypsilanti, Michigan, United States
GSK Investigational Site
Columbia, Missouri, United States
GSK Investigational Site
St Louis, Missouri, United States
GSK Investigational Site
St Louis, Missouri, United States
GSK Investigational Site
Missoula, Montana, United States
GSK Investigational Site
Jersey City, New Jersey, United States
GSK Investigational Site
The Bronx, New York, United States
GSK Investigational Site
Charlotte, North Carolina, United States
GSK Investigational Site
Raleigh, North Carolina, United States
GSK Investigational Site
Rocky Mount, North Carolina, United States
GSK Investigational Site
Salisbury, North Carolina, United States
GSK Investigational Site
Winston-Salem, North Carolina, United States
GSK Investigational Site
Columbus, Ohio, United States
GSK Investigational Site
Dayton, Ohio, United States
GSK Investigational Site
Oklahoma City, Oklahoma, United States
GSK Investigational Site
Tulsa, Oklahoma, United States
GSK Investigational Site
Medford, Oregon, United States
GSK Investigational Site
Portland, Oregon, United States
GSK Investigational Site
Philadelphia, Pennsylvania, United States
GSK Investigational Site
Warwick, Rhode Island, United States
GSK Investigational Site
Charleston, South Carolina, United States
GSK Investigational Site
Little River, South Carolina, United States
GSK Investigational Site
Mt. Pleasant, South Carolina, United States
GSK Investigational Site
Rock Hill, South Carolina, United States
GSK Investigational Site
Bristol, Tennessee, United States
GSK Investigational Site
Knoxville, Tennessee, United States
GSK Investigational Site
Dallas, Texas, United States
GSK Investigational Site
Houston, Texas, United States
GSK Investigational Site
Houston, Texas, United States
GSK Investigational Site
McKinney, Texas, United States
GSK Investigational Site
San Antonio, Texas, United States
GSK Investigational Site
Waco, Texas, United States
GSK Investigational Site
Salt Lake City, Utah, United States
GSK Investigational Site
Norfolk, Virginia, United States
GSK Investigational Site
Williamsburg, Virginia, United States
GSK Investigational Site
Bellevue, Washington, United States
GSK Investigational Site
Bellingham, Washington, United States
GSK Investigational Site
Buenos Aires, , Argentina
GSK Investigational Site
Buenos Aires, , Argentina
GSK Investigational Site
Ciudad Autonoma Buenos Aires, , Argentina
GSK Investigational Site
Ciudad Autonoma de Buenos Aire, , Argentina
GSK Investigational Site
Córdoba, , Argentina
GSK Investigational Site
Mar del Plata, , Argentina
GSK Investigational Site
Mendoza, , Argentina
GSK Investigational Site
Rosario, , Argentina
GSK Investigational Site
Rosario, , Argentina
GSK Investigational Site
Rosario, , Argentina
GSK Investigational Site
San Miguel de Tucumán, , Argentina
GSK Investigational Site
Santa Fe, , Argentina
GSK Investigational Site
Vicente López, , Argentina
GSK Investigational Site
Brussels, , Belgium
GSK Investigational Site
Ghent, , Belgium
GSK Investigational Site
Kortrijk, , Belgium
GSK Investigational Site
Leuven, , Belgium
GSK Investigational Site
Liège, , Belgium
GSK Investigational Site
Mechelen, , Belgium
GSK Investigational Site
Roeselare, , Belgium
GSK Investigational Site
Calgary, Alberta, Canada
GSK Investigational Site
Calgary, Alberta, Canada
GSK Investigational Site
Kelowna, British Columbia, Canada
GSK Investigational Site
Ajax, Ontario, Canada
GSK Investigational Site
Hamilton, Ontario, Canada
GSK Investigational Site
Hamilton, Ontario, Canada
GSK Investigational Site
Toronto, Ontario, Canada
GSK Investigational Site
Windsor, Ontario, Canada
GSK Investigational Site
Greenfield Park, Quebec, Canada
GSK Investigational Site
Montreal, Quebec, Canada
GSK Investigational Site
Montreal, Quebec, Canada
GSK Investigational Site
Québec, Quebec, Canada
GSK Investigational Site
Québec, Quebec, Canada
GSK Investigational Site
Québec, Quebec, Canada
GSK Investigational Site
Québec, Quebec, Canada
GSK Investigational Site
Saint-Charles-Borromée, Quebec, Canada
GSK Investigational Site
Sherbrooke, Quebec, Canada
GSK Investigational Site
Trois-Rivières, Quebec, Canada
GSK Investigational Site
Victoriaville, Quebec, Canada
GSK Investigational Site
Burlington, , Canada
GSK Investigational Site
Floridablanca, , Colombia
GSK Investigational Site
Medellín, , Colombia
GSK Investigational Site
Medellín, , Colombia
GSK Investigational Site
Medellín, , Colombia
GSK Investigational Site
Dijon, , France
GSK Investigational Site
Lille, , France
GSK Investigational Site
Marseille, , France
GSK Investigational Site
Marseille, , France
GSK Investigational Site
Montpellier, , France
GSK Investigational Site
Paris, , France
GSK Investigational Site
Strasbourg, , France
GSK Investigational Site
Toulouse, , France
GSK Investigational Site
Balatonfüred, , Hungary
GSK Investigational Site
Budapest, , Hungary
GSK Investigational Site
Budapest, , Hungary
GSK Investigational Site
Gödöllő, , Hungary
GSK Investigational Site
Hajdúnánás, , Hungary
GSK Investigational Site
Mosonmagyaróvár, , Hungary
GSK Investigational Site
Pécs, , Hungary
GSK Investigational Site
Püspökladány, , Hungary
GSK Investigational Site
Aurangabad, , India
GSK Investigational Site
Bengaluru, , India
GSK Investigational Site
Delhi, , India
GSK Investigational Site
Jaipur, , India
GSK Investigational Site
Kolkata, , India
GSK Investigational Site
Kozhikode, , India
GSK Investigational Site
Nashik, , India
GSK Investigational Site
Nashik, , India
GSK Investigational Site
Pune, , India
GSK Investigational Site
Rohtak, , India
GSK Investigational Site
Thāne, , India
GSK Investigational Site
Ulhasnagar, , India
GSK Investigational Site
Hadera, , Israel
GSK Investigational Site
Haifa, , Israel
GSK Investigational Site
Jerusalem, , Israel
GSK Investigational Site
Petah Tikva, , Israel
GSK Investigational Site
Ramat Gan, , Israel
GSK Investigational Site
Tel Aviv, , Israel
GSK Investigational Site
Alkmaar, , Netherlands
GSK Investigational Site
Arnhem, , Netherlands
GSK Investigational Site
Breda, , Netherlands
GSK Investigational Site
Eindhoven, , Netherlands
GSK Investigational Site
Uden, , Netherlands
GSK Investigational Site
Zutphen, , Netherlands
GSK Investigational Site
Zwolle, , Netherlands
GSK Investigational Site
Bialystok, , Poland
GSK Investigational Site
Bydgoszcz, , Poland
GSK Investigational Site
Bydgoszcz, , Poland
GSK Investigational Site
Lodz, , Poland
GSK Investigational Site
Lodz, , Poland
GSK Investigational Site
Ostrowiec Świętokrzyski, , Poland
GSK Investigational Site
Piaseczno, , Poland
GSK Investigational Site
Rzeszów, , Poland
GSK Investigational Site
Tarnów, , Poland
GSK Investigational Site
Zawadzkie, , Poland
GSK Investigational Site
Bloemfontein, , South Africa
GSK Investigational Site
Durban, , South Africa
GSK Investigational Site
Durban, , South Africa
GSK Investigational Site
George, , South Africa
GSK Investigational Site
Johannesburg, , South Africa
GSK Investigational Site
Johannesburg, , South Africa
GSK Investigational Site
Pretoria, , South Africa
GSK Investigational Site
Somerset West, , South Africa
GSK Investigational Site
Alcobendas, , Spain
GSK Investigational Site
Badalona, , Spain
GSK Investigational Site
Barcelona, , Spain
GSK Investigational Site
Barcelona, , Spain
GSK Investigational Site
Barcelona, , Spain
GSK Investigational Site
Granada, , Spain
GSK Investigational Site
Madrid, , Spain
GSK Investigational Site
Madrid, , Spain
GSK Investigational Site
Málaga, , Spain
GSK Investigational Site
Málaga, , Spain
GSK Investigational Site
Pamplona, , Spain
GSK Investigational Site
Pozuelo de Alarcón, , Spain
GSK Investigational Site
Santiago de Compostela, , Spain
GSK Investigational Site
Belfast, , United Kingdom
GSK Investigational Site
Bristol, , United Kingdom
GSK Investigational Site
Corby, , United Kingdom
GSK Investigational Site
Hayle, , United Kingdom
GSK Investigational Site
Hull, , United Kingdom
GSK Investigational Site
London, , United Kingdom
GSK Investigational Site
Northwood, , United Kingdom
GSK Investigational Site
Orpington, , United Kingdom
GSK Investigational Site
Shipley, , United Kingdom
GSK Investigational Site
Wythenshawe, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Thach T, Dhanabalan K, Nandekar PP, Stauffer S, Heisler I, Alvarado S, Snyder J, Subramanian R. Mechanistic insights into the selective targeting of P2X3 receptor by camlipixant antagonist. J Biol Chem. 2025 Jan;301(1):108109. doi: 10.1016/j.jbc.2024.108109. Epub 2024 Dec 18.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
BUS-P3-01
Identifier Type: OTHER
Identifier Source: secondary_id
2024-513460-26-00
Identifier Type: OTHER
Identifier Source: secondary_id
221850
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.